SCHEMBL29489693

SCHEMBL29489693

O=C(/C=C/c1ccc(O)c(O)c1)CCCCc1ccccc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IAPP P10997 4/20 0.74
ALOX5 P09917 5/20 0.73
APP P05067 3/20 0.64
HSD17B10 Q99714 4/20 0.62
MMP1 P03956 4/20 0.62
MMP2 P08253 4/20 0.62
MMP9 P14780 4/20 0.62
CYP3A4 P08684 3/20 0.62
ALOX15 P16050 3/20 0.62
MAPK1 P28482 3/20 0.62
AKR1B10 O60218 3/20 0.62
TTR P02766 3/20 0.62
AKR1B1 P15121 3/20 0.62
KDM4E B2RXH2 3/20 0.62
ALOX12 P18054 2/20 0.62
MEN1 O00255 2/20 0.62
ALDH1A1 P00352 2/20 0.62
LMNA P02545 2/20 0.62
MAPT P10636 2/20 0.62
HPGD P15428 2/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8392957 1.00 IAPP (0.74) IAPPALOX5APPHSD17B10MMP1
SCHEMBL8392954 1.00 IAPP (0.74) IAPPALOX5APPHSD17B10MMP1
SCHEMBL14964001 0.96 ALOX5 (0.67) IAPPALOX5APPHSD17B10MMP1
SCHEMBL29689081 0.96 ALOX5 (0.67) IAPPALOX5APPHSD17B10MMP1
SCHEMBL4545217 0.90 ALOX5 (0.67) IAPPALOX5APPHSD17B10MMP1
SCHEMBL30449722 0.90 ALOX5 (0.67) IAPPALOX5APPHSD17B10MMP1
SCHEMBL1976133 0.89 IAPP (0.66) IAPPALOX5APPHSD17B10MMP1
SCHEMBL1976131 0.89 IAPP (0.66) IAPPALOX5APPHSD17B10MMP1
SCHEMBL9694301 0.87 ALOX5 (0.67) IAPPALOX5APPHSD17B10MMP1
SCHEMBL29489701 0.86 ALOX5 (0.65) IAPPALOX5MMP1MMP2MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240277714-A1 USE OF SOS1 INHIBITORS WITH RAS INHIBITORS TO TREAT CANCERS Revolution Medicines, Inc. 2024-08-22 US disclosed
US-20240108630-A1 METHODS FOR INHIBITING RAS Revolution Medicines, Inc. 2024-04-04 US disclosed
CN-114921892-B Powder-coated fabric and preparation method thereof 无锡市亿润纺织有限公司 2024-03-26 CN disclosed
US-20220235134-A1 ANTI-B7-H3 ANTIBODIES SINGLE CELL TECHNOLOGY, INC. (US) 2022-07-28 US disclosed
EP-3976660-A1 ANTI-B7-H3 ANTIBODIES Single Cell Technology, Inc. (US) 2022-04-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240277714-A1 USE OF SOS1 INHIBITORS WITH RAS INHIBITORS TO TREAT CANCERS SOS1, HRAS, KRAS IAPP 2592/4885ALOX5 4441/4885APP 3618/4885
US-20240108630-A1 METHODS FOR INHIBITING RAS KRAS, HRAS, NRAS IAPP 3776/4885ALOX5 4608/4885APP 4353/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.